- Home
- GRI vs KRKR Comparison
GRI vs KRKR Comparison
Compare GRI & KRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- KRKR
- Stock Information
- Founded
- GRI 2018
- KRKR 2010
- Country
- GRI United States
- KRKR China
- Employees
- GRI N/A
- KRKR N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- KRKR Business Services
- Sector
- GRI Health Care
- KRKR Consumer Discretionary
- Exchange
- GRI Nasdaq
- KRKR Nasdaq
- Market Cap
- GRI 6.1M
- KRKR 6.6M
- IPO Year
- GRI N/A
- KRKR 2019
- Fundamental
- Price
- GRI $0.78
- KRKR $3.38
- Analyst Decision
- GRI Strong Buy
- KRKR
- Analyst Count
- GRI 2
- KRKR 0
- Target Price
- GRI $11.50
- KRKR N/A
- AVG Volume (30 Days)
- GRI 377.5K
- KRKR 22.4K
- Earning Date
- GRI 11-14-2024
- KRKR 12-31-2024
- Dividend Yield
- GRI N/A
- KRKR N/A
- EPS Growth
- GRI N/A
- KRKR N/A
- EPS
- GRI N/A
- KRKR N/A
- Revenue
- GRI N/A
- KRKR $41,654,350.00
- Revenue This Year
- GRI N/A
- KRKR $45.99
- Revenue Next Year
- GRI N/A
- KRKR $31.46
- P/E Ratio
- GRI N/A
- KRKR N/A
- Revenue Growth
- GRI N/A
- KRKR N/A
- 52 Week Low
- GRI $0.30
- KRKR $2.76
- 52 Week High
- GRI $65.00
- KRKR $12.60
- Technical
- Relative Strength Index (RSI)
- GRI 49.02
- KRKR 44.02
- Support Level
- GRI $0.75
- KRKR $3.10
- Resistance Level
- GRI $1.00
- KRKR $3.69
- Average True Range (ATR)
- GRI 0.09
- KRKR 0.35
- MACD
- GRI -0.00
- KRKR 0.03
- Stochastic Oscillator
- GRI 38.93
- KRKR 41.74
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.